Metabolism - Clinical and Experimental
Volume 44, Issue 6 , Pages 705-711, June 1995

Amylin-mediated reduction in insulin sensitivity corresponds to reduced insulin receptor kinase activity in the rat in vivo

  • Michael Bryer-Ash

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Michael Bryer-Ash, MD, Department of Medicine SL-53, Tulane University Medical Center, 1430 Tulane Ave, New Orleans, LA 70112.
    • Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USA
    • Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
    • Department of Medicine, University of Texas Medical Branch, Galveston, TX, USA
  • ,
  • Lezley Follett

      Affiliations

    • Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USA
    • Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
    • Department of Medicine, University of Texas Medical Branch, Galveston, TX, USA
  • ,
  • Norman Hodges

      Affiliations

    • Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USA
    • Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
    • Department of Medicine, University of Texas Medical Branch, Galveston, TX, USA
  • ,
  • Sunil Wimalawansa

      Affiliations

    • Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USA
    • Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
    • Department of Medicine, University of Texas Medical Branch, Galveston, TX, USA

Received 26 June 1993; accepted 3 October 1994.

Abstract 

Studies were undertaken to elucidate further the mechanism whereby the pancreatic peptide amylin induces insulin resistance. Sixteen male Sprague-Dawley rats underwent hyperinsulinemic (14 pmol/kg/min, 0 to 120 minutes) euglycemic clamps in the presence or absence of amylin (500 pmol/kg/min, 60 to 120 minutes). Amylin induced insulin resistance at both the hepatic level (mean ± SE: hepatic glucose output [HGO] with amylin 1.4 ± 0.2 v without amylin −1.9 ± 0.3 mmol/kg/h, P < .001) and peripheral level (glucose disposal [Rd] with amylin 5.0 ± 0.2 v without amylin 8.5 ± 0.6 mmol/kg/h, P < .001). Serum insulin levels were similar in the presence or absence of amylin alone (661 ± 89 v 636 ± 50 pmol/L, respectively, P = NS), but were significantly less when somatostatin (SRIF) was simultaneously infused (408 ± 15 pmol/ L, P < .02 v the other two groups). This suggests that endogenous insulin production was not suppressed by amylin under these study conditions. Similar findings were obtained in 18 animals in the absence of exogenous insulin infusion. In vitro kinase activity toward histone of skeletal muscle insulin receptors (IRs) activated by insulin in vivo was reduced in the presence of amylin to 6.0 ± 0.8 versus 9.1 ± 1.2 fmol phosphate into histone (insulin-infused) and 3.9 ± 0.7 versus 6.9 ± 1.4 (non-insulin-infused; P < .03 by ANOVA). Serum calcium was significantly decreased in amylin-treated animals (1.93 ± 0.04 v 2.30 ± 0.05 mmol/L, P < .001). The ability of insulin to promote Rd was decreased in the presence of amylin (12.0 ± 1.4 v 19.7 ± 2.7 mmol/ kg/h per nmol/L insulin, P < .03), but the relationship between IR kinase activity and Rd was similar in the presence or absence of amylin (0.9 ± 0.1 v 1.1 ± 0.1 mmol/kg/h per fmol PO4, P = NS). The data suggest that in vivo amylin may induce insulin resistance at or proximal to IR kinase.

No full text is available. To read the body of this article, please view the PDF online.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by a grant-in-aid from the Canadian Diabetes Association and the University Hospital Foundation, University Hospital, Vancouver, BC. M.B.-A, was the recipient of a scholarship from the British Columbia Health Research Foundation. L.F. was supported by a student research award from the Juvenile Diabetes Foundation Canada.

PII: 0026-0495(95)90181-7

Metabolism - Clinical and Experimental
Volume 44, Issue 6 , Pages 705-711, June 1995